Study of Glycemic Variability, Hypoglycemia Using Continuous Glucose Monitoring in Type 2 Diabetes Mellitus Changed from Basal-Bolus Therapy to Basal-GLP-1 RA Therapy

Not Applicable

• Conditions: Type 2 Diabetes Mellitus

• Registration Number: JPRN-UMIN000042895
• Lead Sponsor: Department of Diabetes and Endocrinology,Sapporo City General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-12-31
• Study Start: 2021-01-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with contraindicated duraglutide

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time Below Range and Time In Range for 3 days before and after treatment change.

Secondary Outcome Measures

Name	Time	Method
Mean glucose levels, %CV for 3 days before and after treatment change and HbA1c, BMI immediately before and one month after the channge.